✨ Free AI Report
DexCom, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research DexCom, Inc.
Company Research

DexCom, Inc.: Business Overview, Financials & Competitive Analysis

DexCom, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Market-leading CGM company with strong growth momentum, improving margins, and expanding addressable market through Stelo and international expansion. FY 2025 revenue reached approximately $4.662 billion, an increase of 16% over 2024. The company demonstrated a net margin of 17.94% and a return on equity of 32.12%. Operating margins expanded by.

What is DexCom, Inc.'s industry? DexCom, Inc. (dexcom.com) operates in Medical Devices - Continuous Glucose Monitoring (CGM) / Diabetes Management. AskCyborg classifies DexCom, Inc. under Medical Devices - Continuous Glucose Monitoring (CGM) / Diabetes Management in its company registry.

DexCom is a medical device company that sells continuous glucose monitoring (CGM) systems that efficiently manage diabetes and metabolic conditions by tracking glucose levels every few minutes. Founded in 1999, Dexcom...

8/ 10Strong

Cyborg Score thesis

Market-leading CGM company with strong growth momentum, improving margins, and expanding addressable market through Stelo and...

Read the full analyst-debate transcript →
Industry Medical Devices - Continuous Glucose Monitoring (CGM) / Diabetes Management
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest DexCom, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for DexCom, Inc.

AskCyborg analysts argue the bull and bear cases for DexCom, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
DexCom, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

DexCom, Inc. Overview

Pro stress-test →

DexCom is a medical device company that sells continuous glucose monitoring (CGM) systems that efficiently manage diabetes and metabolic conditions by tracking glucose levels every few minutes. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years.

Strategic Profile

Pro stress-test →

The company designs and commercializes continuous glucose monitoring systems that serve as an alternative to traditional blood glucose meters and is evolving its CGM systems to provide integration with insulin pumps for automatic insulin delivery. Growth is driven by higher sensor volumes, the Stelo rollout (for prediabetes and Type 2 patients), and further international expansion.

Competitive Landscape

Pro stress-test →

Intensifying CGM competition presents challenges, particularly in DexCom's core insulin-intensive segment. Major competitors include Senseonics (Eversense system) and Tandem Diabetes Care, which offers competing continuous glucose monitoring solutions. DexCom's CGMs are available through medical equipment distributors and retail pharmacies.

Industry Context

DexCom, Inc. operates in Medical Devices - Continuous Glucose Monitoring (CGM) / Diabetes Management.

Key facts

Founded: 1999 · Headquarters: San Diego, US · Revenue: $4.66B · Market cap: $27.3B

What the analysts stress-tested

The top findings that survived the multi-agent debate for DexCom, Inc..

  • Q4 2025 results beat expectations with $0.68 EPS vs. $0.65 consensus and $1.26B in revenue (≈13% YoY growth).
  • 2026 revenue guidance of $5.16-$5.25 billion tied to sensor volumes, Stelo rollout, and international expansion.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Q4 2025 results: $1.26B quarterly revenue (+13% YoY), $0.68 EPS, beating analyst expectations
  • January 2026Full launch of G7 15 Day continuous glucose monitoring system across all U.S. distribution channels
  • +1 moreTrack every material event for DexCom, Inc. as it happens. Explore monitoring →
Get alerted when DexCom, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

EversenseImplantable continuous glucose monitoring system→t:slim X2Insulin pump with integrated CGM compatibility→FreeStyle LibreFlash glucose monitoring system→

Compare DexCom, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

DexCom, Inc. operates in Medical Devices - Continuous Glucose Monitoring (CGM) / Diabetes Management. See how the rest of the sector scores on the Cyborg framework.

Browse Medical Devices - Continuous Glucose Monitoring (CGM) / Diabetes Management research →
NEW · MCP server

Ask your AI assistant about DexCom, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare DexCom, Inc. and its top competitor on Cyborg Score”
“What did DexCom, Inc. do this quarter?”
“Is DexCom, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does DexCom, Inc. do?+
DexCom is a medical device company that sells continuous glucose monitoring (CGM) systems that efficiently manage diabetes and metabolic conditions by tracking glucose levels every few minutes. Founded in 1999, Dexcom...
What is DexCom, Inc.'s Cyborg Score?+
DexCom, Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are DexCom, Inc.'s main competitors?+
Named competitors include Eversense, t:slim X2, FreeStyle Libre. The full competitive landscape is in the AskCyborg report.
How can I get the full DexCom, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the DexCom, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track DexCom, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Medical Devices - Continuous Glucose Monitoring (CGM) research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8DexCom, Inc.